# Neogen Corporation (NEOG) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.83, market value $2.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Neogen Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.31**. A PEG of 0.31 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.0×**. Each dollar of revenue is priced at 3.0×.
- **Price / book: 1.2×**. The shares trade at 1.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 33.7×**. Enterprise value is 33.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 1.2%** (5-yr avg -0.8%). Free cash flow equals 1.2% of the market value, above its five-year average of -0.8%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Gross margin: 46.9%**. Neogen Corporation keeps 46.9% of revenue after the direct cost of what it sells.
- **Operating margin: -2.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -0.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -0.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -0.6%**. Return on all capital, debt included, is -0.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -0.2%**. Each dollar of assets produces -0.2% of profit.

## Growth
- **Revenue growth (1 yr): -2.7%** (3-yr 1.9%/yr, 5-yr 13.2%/yr). Revenue fell 2.7% over the last year, against 13.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 99.2%**. Earnings per share rose 99.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.38**. Debt is 0.38 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 6.4×**. It would take 6.4 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 3.82** (quick 3.82). Current assets cover the next year's liabilities 3.82 times.
- **Altman Z-score: 2.51**. A Z-score of 2.51 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Neogen Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (3 analysts). 3 analysts cover Neogen Corporation; the consensus is buy, with an average price target of $13.33 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 106.1%** (YTD 69.2%, 3-mo 32.9%). The shares are up 106.1% over twelve months including dividends.
- **From 52-week high: -7.9%** (141.4% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 1.54** (volatility 61%). Beta of 1.54 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NEOG · Page: https://foliofundamentals.com/stocks/neog

Not investment advice.